Go online to PeerView.com/UVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest “How I Think, How I Treat” webcast, leading experts, John C. Byrd, MD, Alexey V. Danilov, MD, PhD, and Nicole Lamanna, MD, explore the current evidence that underlies the use of first- and second-generation BTK inhibitors in diseases such as CLL, MCL, and others. They also share their personal insights and intra-institutional experiences in order to illustrate what the availability of BTK inhibitor therapy has meant for their practices. Learn how the experts have adapted to the BTK era! Upon completion of this activity, participants should be better able to: Describe the anticancer mechanisms of first- and second-generation BTK inhibitors, Cite updated guidelines and evidence surrounding the efficacy and safety of first- and second-generation BTK inhibitors in the management of B-cell cancers, including CLL and MCL, among others, Develop appropriate single-agent, sequential, or combination strategies using BTK inhibitors in the management of patients with B-cell malignancies, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with B-cell cancer.